摘要
甘草次酸属五环三萜类化合物,是中药甘草的重要活性成分,具有抗炎、抗病毒、抗溃疡、免疫调节等广泛的药理活性,近年来发现甘草次酸具有广谱的抗肿瘤作用,其抗肿瘤作用机制也得到了广泛研究。肿瘤多药耐药机制十分复杂,且目前在肿瘤的临床治疗中,仍然是化疗所面临的障碍和挑战。甘草次酸具有药理活性好,低毒性的优点,已经展现出对肿瘤多药耐药的逆转作用,具有在多种化疗药物引起的化学抵抗中成为化疗增敏剂的潜力。本文论述了肿瘤多药耐药的发生机制及甘草次酸逆转肿瘤多药耐药机制研究进展。
Glycyrrhetinic acid(GA) is belong to pentacyclic triterpene which is a major active ingredient in licorice, a famous traditional Chinese medicine. It has the effect of anti-inflammation, anti-virus, anti-ulcer and immune regulation. In recent years,it has been found that GA also has high broad spectrum anti-tumor activity, and its anti-tumor mechanism has attracted a great deal of attention. The mechanism of multidrug resistance(MDR) is very complex, and in current, MDR is still the obstacles and challenges of chemotherapy in clinical treatment of tumors. GA has the advantages of good pharmacological activity and low toxicity. The latest research shows that GA can reverse the multidrug resistance of tumor, but also can become a chemosensitizer in chemical resistance caused by various chemotherapy drugs. This paper discusses the mechanism of MDR, and the research progress of GA in reversing the multidrug resistance is reviewed in this paper.
引文
[1]BINKHATHLAN Z,LAVASANIFAR A.P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer:current status and future perspectives[J].Curr Cancer Drug Targets,2013,13(3):326-346.
[2]MCDEVITT C A,CALLAGHAN R.How can we best use structural information on P-glycoprotein to design inhibitors?[J].Pharmacol Ther,2007,113(2):429-441.
[3]YANG S S,LIU A L,ZHOU Q,et al.Advances on Chinese materia medica-chemical drug interactions mediated by P-glycoprotein[J].Chin Tradit Herb Drugs(中草药),2017,48(15):3189-3197.
[4]LIU H Y.Research progress on Chinese materia medica for reversing tumor multidrugresistance[J].Chin Tradit Herb Drugs(中草药),2015,46(7):1096-1102.
[5]刘嘉,曾庆琪.中药活性成分逆转肿瘤多药耐药的研究进展[J].中医药信息,2011,28(5):112-114.
[6]WANG H J,ZHANG M Z,LIU X J,et al.Research progress of triptolide's reversal effect on multi-drug resistance[J].Chin J Exp Tradit Med Form(中国实验方剂学杂志),2016(10):229-234.
[7]LALLEMAND B,GELBCKE M,DUBOIS J,et al.Structure-activity relationship analyses of glycyrrhetinic acid derivatives as anticancer agents[J].Mini Rev Med Chem,2011,11(10):881-887.
[8]雍建平,张毓洪,赵巍,等.甘草次酸及甘草次酸衍生物药理活性研究进展[J].时珍国医国药,2010,21(12):3335-3337.
[9]WANG C,FANG F P,CAI H L.Research progress of ABCmembrane transporters and their regulation in tumor drug resistance and new mechanism of detoxification[J].Chin Pharm J(中国药学杂志),2017,52(22):1961-1965.
[10]LI Z H,YAN M,CAO L J,et al.Glycyrrhetinic acid accelerates the clearance of triptolide through P-gp in vitro[J].Phytother Res,2017,31(7):1090.Doi:10.1002/ptr.5831.
[11]THORNALLEY P,RABBANI N.Glyoxalase in tumourigenesis and multidrug resistance[J].Semin Cell Dev Biol,2011,22(3):318-325.
[12]毛俊俊,张英.COX-2表达与肿瘤多药耐药相关性的研究进展[J].海峡药学,2011,23(6):22-24.
[13]SUI H,FAN Z Z,LI Q.Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells[J].J Int Med Res,2012,40(2):426-435.
[14]XIE X,TANG B,ZHOU J,et al.Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine[J].Oncol Rep,2013,30(2):773-782.
[15]XIE L,HUANG G.The relationship between multidrug resistance(MDR)of tumor and anti-apoptosis[J].Fudan Univ J Med Sci(复旦学报:医学版),2012,39(4):428-432.
[16]何娟,刘晓磊,彭文兴.P-糖蛋白介导的肿瘤多药耐药逆转机制研究进展[J].中国药房,2006,17(3):218-220.
[17]JEMNITZ K,HEREDI S K J,IOJA E,et al.ABCC2/Abcc2:a multispecific transporter with dominant excretory functions[J].Drug Metabol Rev,2010,42(3):402-436.
[18]JI H,WANG B G.The Research Progress on Breast Cancer Resistance Protein(BCRP/ABCG2)[J].Anti-tumor Pharm(肿瘤预防与治疗),2013(5):246-250.
[19]YOSHIDA N,TAKADA T,YAMAMURA Y,et al.Inhibitory effects of terpenoids on multidrug resistance-associated protein2-and breast cancer resistance protein-mediated transport[J].Drug Metab Dispos,2008,36(7):1206-1211.
[20]YE X,SHEN Z X.Recent progress in drug-resistance modulating activity of glyoxalase inhibitors[J].J Int Oncol(国际肿瘤学杂志),2006,33(10):747-750.
[21]ZHU C Y,LI Z H,WANG F T.An update on progress in glyoxalaseⅠinhibitor as an emerging class of anticancer agents[J].Pharm Clin Res(药学与临床研究),2011,19(4):337-342.
[22]DU H,LIU M,YU A,et al.Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin[J].Int JPharm,2017,523(1):427-438.
